share_log

SC 13G: Statement of acquisition of beneficial ownership by individuals-Bristol-Myers Squibb Company(8.40%)

SC 13G: Statement of acquisition of beneficial ownership by individuals-Bristol-Myers Squibb Company(8.40%)

SC 13G:超過5%持股股東披露文件-Bristol-Myers Squibb Company(8.40%)
美股SEC公告 ·  10/04 16:25

Moomoo AI 已提取核心訊息

Bristol-Myers Squibb Company, a biopharmaceutical firm incorporated in Delaware, has filed a Schedule 13G with the United States Securities and Exchange Commission on October 4, 2024, indicating a significant investment in Prime Medicine, Inc. According to the filing, Bristol-Myers Squibb now holds 11,006,163 shares of Prime Medicine's common stock, which represents 8.40% of the company's class of securities. This stake acquisition follows a Securities Purchase Agreement between the two companies, finalized on September 30, 2024. The filing clarifies that the shares were not purchased with the intention of changing or influencing the control of Prime Medicine, Inc.
Bristol-Myers Squibb Company, a biopharmaceutical firm incorporated in Delaware, has filed a Schedule 13G with the United States Securities and Exchange Commission on October 4, 2024, indicating a significant investment in Prime Medicine, Inc. According to the filing, Bristol-Myers Squibb now holds 11,006,163 shares of Prime Medicine's common stock, which represents 8.40% of the company's class of securities. This stake acquisition follows a Securities Purchase Agreement between the two companies, finalized on September 30, 2024. The filing clarifies that the shares were not purchased with the intention of changing or influencing the control of Prime Medicine, Inc.
施貴寶公司是一家生物製藥公司,成立於特拉華州,已於2024年10月4日向美國證券交易委員會提交了13G表,表明對Prime Medicine公司進行重大投資。根據文件,施貴寶現持有Prime Medicine普通股11006163股,佔公司證券類別的8.40%。這一股份收購是在2024年9月30日兩家公司之間達成的證券購買協議之後進行的。申報澄清,這些股份並非出於改變或影響Prime Medicine公司控制權的意圖而購買。
施貴寶公司是一家生物製藥公司,成立於特拉華州,已於2024年10月4日向美國證券交易委員會提交了13G表,表明對Prime Medicine公司進行重大投資。根據文件,施貴寶現持有Prime Medicine普通股11006163股,佔公司證券類別的8.40%。這一股份收購是在2024年9月30日兩家公司之間達成的證券購買協議之後進行的。申報澄清,這些股份並非出於改變或影響Prime Medicine公司控制權的意圖而購買。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息